@article{JGO7026,
author = {Nishi Kothari and Eric Mellon and Sarah E. Hoffe and Jessica Frakes and Ravi Shridhar and Jose Pimiento and Ken Meredith and Nam D. Tran and Nadia Saeed and Khaldoun Almhanna},
title = {Outcomes in patients with brain metastasis from esophageal carcinoma},
journal = {Journal of Gastrointestinal Oncology},
volume = {7},
number = {4},
year = {2016},
keywords = {},
abstract = {Background: Brain metastases from esophageal carcinoma have historically been rare and associated with poor prognosis. With improvements in systemic disease control, the incidence of brain metastases is expected to rise. To better inform management decisions, we sought to identify factors associated with survival in patients with brain metastasis from esophageal cancer.
Methods: We retrospectively identified 49 patients with brain metastasis from stage I–IV primary esophageal cancer treated with surgery, radiation, or a combination of modalities at our tertiary referral center between 1998 and 2015. Medical records were reviewed to collect demographic and clinical information.
Results: Median age at diagnosis of the primary esophageal cancer was 60 years. Forty-one (84%) patients were male and forty patients (82%) had adenocarcinoma. Median overall survival (MS) following esophageal cancer diagnosis was 24 months (range, 3–71 months), and median survival after the identification of brain metastases was 5 months (range, 1–52 months). On univariate analysis, only patients with poor Karnofsky performance status (KPS },
issn = {2219-679X}, url = {https://jgo.amegroups.org/article/view/7026}
}